{"id":"NCT00505687","sponsor":"UCB Pharma","briefTitle":"An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease","officialTitle":"A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2007-07-23","resultsPosted":"2010-01-12","lastUpdate":"2014-10-02"},"enrollment":186,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":["Neupro"]}],"arms":[{"label":"Rotigotine","type":"EXPERIMENTAL"}],"summary":"The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.","primaryOutcome":{"measure":"Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","timeFrame":"four years","effectByArm":[{"arm":"Rotigotine","deltaMin":170,"sd":null}],"pValues":[]},"eligibility":{"minAge":"31 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":26,"countries":["United States","Austria","Germany","Israel","Italy","South Africa","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":186},"commonTop":["Somnolence","Oedema peripheral","Fall","Application site erythema","Insomnia"]}}